Hüttner Felix J, Klotz Rosa, Ulrich Alexis, Büchler Markus W, Diener Markus K
Department of General, Visceral and Transplant Surgery, University of Heidelberg, Im Neuenheimer Feld 110, Heidelberg, Germany, 69120.
Cochrane Database Syst Rev. 2016 Sep 30;9(9):CD011862. doi: 10.1002/14651858.CD011862.pub2.
Pancreatic cancer remains one of the five leading causes of cancer deaths in industrialized nations. For adenocarcinomas in the head of the gland and premalignant lesions, partial pancreaticoduodenectomy represents the standard treatment for resectable tumours. The gastro- or duodenojejunostomy after partial pancreaticoduodenectomy can be reestablished via either an antecolic or a retrocolic route. The debate about the more favourable technique for bowel reconstruction is ongoing.
To compare the effectiveness and safety of antecolic and retrocolic gastro- or duodenojejunostomy after partial pancreaticoduodenectomy.
We conducted a systematic literature search on 29 September 2015 to identify all randomised controlled trials in the Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library 2015, issue 9, MEDLINE (1946 to September 2015), and EMBASE (1974 to September 2015). We applied no language restrictions. We handsearched reference lists of identified trials to identify further relevant trials, and searched the trial registry clinicaltrials.gov for ongoing trials.
We considered all randomised controlled trials that compared antecolic versus retrocolic reconstruction of bowel continuity after partial pancreaticoduodenectomy for any given indication to be eligible.
Two review authors independently screened the identified references and extracted data from the included trials. The same two review authors independently assessed risk of bias of included trials, according to standard Cochrane methodology. We used a random-effects model to pool the results of the individual trials in a meta-analysis. We used odds ratios to compare binary outcomes and mean differences for continuous outcomes.
Of a total of 216 citations identified by the systematic literature search, we included six randomised controlled trials (reported in nine publications), with a total of 576 participants. We identified a moderate heterogeneity of methodological quality and risk of bias of the included trials. None of the pooled results for our main outcomes of interest showed significant differences: delayed gastric emptying (OR 0.60; 95% CI 0.31 to 1.18; P = 0.14), mortality (RD -0.01; 95% CI -0.03 to 0.02; P = 0.72), postoperative pancreatic fistula (OR 0.98; 95% CI 0.65 to 1.47; P = 0.92), postoperative haemorrhage (OR 0.79; 95% CI 0.38 to 1.65; P = 0.53), intra-abdominal abscess (OR 0.93; 95% CI 0.52 to 1.67; P = 0.82), bile leakage (OR 0.89; 95% CI 0.36 to 2.15; P = 0.79), reoperation rate (OR 0.59; 95% CI 0.27 to 1.31; P = 0.20), and length of hospital stay (MD -0.67; 95%CI -2.85 to 1.51; P = 0.55). Furthermore, the perioperative outcomes duration of operation, intraoperative blood loss and time to NGT removal showed no relevant differences. Only one trial reported quality of life, on a subgroup of participants, also without a significant difference between the two groups at any time point. The overall quality of the evidence was only low to moderate, due to heterogeneity, some inconsistency and risk of bias in the included trials.
AUTHORS' CONCLUSIONS: There was low to moderate quality evidence suggesting no significant differences in morbidity, mortality, length of hospital stay, or quality of life between antecolic and retrocolic reconstruction routes for gastro- or duodenojejunostomy. Due to heterogeneity in definitions of the endpoints between trials, and differences in postoperative management, future research should be based on clearly defined endpoints and standardised perioperative management, to potentially elucidate differences between these two procedures. Novel strategies should be evaluated for prophylaxis and treatment of common complications, such as delayed gastric emptying.
在工业化国家,胰腺癌仍然是癌症死亡的五大主要原因之一。对于胰腺头部的腺癌和癌前病变,胰十二指肠切除术是可切除肿瘤的标准治疗方法。胰十二指肠切除术后的胃肠或十二指肠空肠吻合可以通过结肠前或结肠后途径重建。关于更有利的肠道重建技术的争论仍在继续。
比较胰十二指肠切除术后结肠前和结肠后胃肠或十二指肠空肠吻合的有效性和安全性。
我们于2015年9月29日进行了系统的文献检索,以识别Cochrane对照试验中心注册库(CENTRAL)、《Cochrane图书馆》2015年第9期、MEDLINE(1946年至2015年9月)和EMBASE(1974年至2015年9月)中的所有随机对照试验。我们没有设置语言限制。我们手工检索了已识别试验的参考文献列表以识别其他相关试验,并在试验注册库clinicaltrials.gov中搜索正在进行的试验。
我们认为所有比较胰十二指肠切除术后结肠前与结肠后肠连续性重建的随机对照试验,无论其特定适应症如何,均符合纳入标准。
两位综述作者独立筛选已识别的参考文献,并从纳入的试验中提取数据。同样的两位综述作者根据Cochrane标准方法独立评估纳入试验的偏倚风险。我们使用随机效应模型在荟萃分析中汇总各个试验的结果。我们使用比值比来比较二元结局,使用均值差来比较连续结局。
在系统文献检索中识别出的总共216篇文献中,我们纳入了6项随机对照试验(在9篇出版物中报道),共有576名参与者。我们发现纳入试验的方法学质量和偏倚风险存在中度异质性。我们感兴趣的主要结局的汇总结果均未显示出显著差异:胃排空延迟(比值比0.60;95%置信区间0.31至1.18;P = 0.14)、死亡率(风险差-0.01;95%置信区间-0.03至0.02;P = 0.72)、术后胰瘘(比值比0.98;95%置信区间0.65至1.47;P = 0.92)、术后出血(比值比0.79;95%置信区间0.38至1.65;P = 0.53)、腹腔内脓肿(比值比0.93;95%置信区间0.52至1.67;P = 0.82)、胆漏(比值比0.89;95%置信区间0.36至2.15;P = 0.79)、再次手术率(比值比0.59;95%置信区间0.27至1.31;P = 0.20)以及住院时间(均值差-0.67;95%置信区间-2.85至1.51;P = 0.55)。此外,围手术期结局手术持续时间、术中失血和鼻胃管拔除时间也没有相关差异。只有一项试验报告了参与者亚组的生活质量,两组在任何时间点也没有显著差异。由于纳入试验存在异质性、一些不一致性和偏倚风险,证据的总体质量仅为低到中等。
有低到中等质量的证据表明,结肠前和结肠后胃肠或十二指肠空肠吻合重建途径在发病率、死亡率、住院时间或生活质量方面没有显著差异。由于试验之间终点定义的异质性以及术后管理的差异,未来的研究应基于明确界定的终点和标准化的围手术期管理,以潜在地阐明这两种手术方法之间的差异。应评估预防和治疗常见并发症(如胃排空延迟)的新策略。